Toby Eyre, CLL specialist at Oxford University Hospitals, shared on X:
“Look out for important primary analysis of UK MCL biobank at EHA2024.
Mant et al N=588, Active observation in 38% (N=222) of prospectively identified MCL patients.
Delaying initiation of treatment in indolent Mantel Cell Lymphoma does not worsen survival outcomes versus immediate treatment.
Valid management strategy.”
Source: Toby Eyre/X